• LORCASERIN CHEMBL360328 FDA Approved

    Alternate Names:

    Lorcaserin
    1H-3-BENZAZEPINE, 8-CHLORO-2,3,4,5-TETRAHYDRO-1-METHYL-, (1R)-
    (5R)-7-CHLORO-5-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE
    W-5409
    FT-0670852
    TX-017673
    AB0148401
    HY-11093
    HE113886
    BC224451
    AK101075
    AJ-56780
    NCGC00182550-02
    CS-1232
    AN-6779
    AM81248
    AB52744
    637E494O0Z
    TOX21_113018_1
    AKOS006326204
    BDBM50161646
    ANW-60436
    TOX21_113018
    ZINC6733300
    ACN-S001920
    XTTZERNUQAFMOF-QMMMGPOBSA-N
    CTK8B8482
    GTPL2941
    SCHEMBL169382
    LORCASERIN [INN]
    LORCASERIN;
    BELVIQREG
    CAS-616202-92-7
    (1R)-8-CHLORO-2,3,4,5-TETRAHYDRO-1-METHYL-1H-3-BENZAZEPINE
    DSSTOX_GSID_48659
    DSSTOX_RID_82856
    DSSTOX_CID_28585
    NCGC00182550-01
    (1R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE
    CHEBI:65353
    (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE
    UNII-637E494O0Z
    (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINE
    616202-92-7
    11658860
    10-CHLORO-2-METHYL-4-AZABICYCLO[5.4.0]UNDECA-8,10,12-TRIENE
    DCL000872
    CID11658860
    AR-10A
    MOLPORT-005-942-408
    CHEBI:401194
    TL80074203
    AC-553
    LS-193332
    Lorqess
    Belviq XR Extended Release Extended Release
    Belviq
    DB04871
    135650530
    2941

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antiobesity agent
    Drug Categories serotonin modulators
    Drug Categories heterocyclic compounds, 2-ring
    Drug Categories heterocyclic compounds
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 cyp2d6 substrates
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (moderate)
    Drug Categories cytochrome p-450 cyp2d6 inhibitors
    Drug Categories cytochrome p-450 cyp2c19 substrates
    Drug Categories cytochrome p-450 cyp2b6 substrates
    Drug Categories cytochrome p-450 cyp2a6 substrates
    Drug Categories cytochrome p-450 cyp1a2 substrates
    Drug Categories centrally acting antiobesity products
    Drug Categories antiobesity preparations, excl. diet products
    Drug Categories alimentary tract and metabolism
    Drug Groups approved
    Drug Type small molecule
    (1 More Sources)